Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...
Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...
InvestorsHub on MSN
Nektar posts mixed phase 2b data for alopecia areata treatment
Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback